Rimidi Enhances Integration with Dexcom, Adds Glycemic Risk Index to Diabetes Platform

Rimidi, a clinical management platform aimed at optimising clinical workflows, enhancing patient experiences, and achieving quality objectives, has announced significant enhancements to its diabetes management platform. These improvements include the integration of the Glycemic Risk Index (GRI) as an emerging tool for managing patient and population outcomes.

Rimidi has achieved this integration by partnering with Dexcom, a renowned global leader in real-time continuous glucose monitoring (CGM) for individuals with diabetes. By collaborating with Dexcom, Rimidi can incorporate CGM data and GRI into its platform and clinical workflows, thereby enabling more proactive and personalised diabetes management across populations, ultimately leading to better care decisions.

The upgraded Rimidi diabetes management platform now includes various metrics designed to advance care management. These metrics encompass:

• Time in Range (TIR): This metric measures the amount of time a patient's blood glucose remains within the target range during a specific period, typically two weeks. The target range is typically between 70 and 180 mg/dL. Leveraging CGM data, TIR provides insights into the frequency of blood glucose levels falling within the target range as opposed to being too high (hyperglycemia) or too low (hypoglycemia). TIR is widely regarded as the gold standard for managing and interpreting CGM data. Rimidi's platform presents TIR values for target glucose, as well as additional categories such as low, very low, high, and very high glucose levels.

• Glycemic Risk Index: Developed by the Diabetes Technology Society, the Glycemic Risk Index is an actionable metric used to describe the quality of glycemia in CGM tracking. This metric enables the assessment of a patient's progress over time, facilitates population management, and predicts outcomes in intervention studies. The composite score derived from the Glycemic Risk Index is believed to better correlate with the risk of complications and aids in identifying areas where therapy adjustments are necessary. Although the use of the Glycemic Risk Index in clinical practice is still in its early stages of adoption, it holds significant promise.

By leveraging these enhanced metrics, Rimidi aims to empower clinicians with valuable insights and enable them to make informed decisions for improving glycemic control, thereby enhancing patient outcomes and experiences in the realm of diabetes management.

Click here to read the original news story.